DOI: 10.36347/sasjs.2021.v07i07.002

Pages: 358-360

Malignant tumors of the small intestine are rare, accounting for between 1 and 6% of tumors of the digestive tract. Adenocarcinoma is the most common histologic subtype, accounting for approximately 35% to 45% of all tumors. It can occur sporadically, or in association with genetic diseases or chronic inflammatory bowel disease. Because the small intestine is relatively inaccessible by endoscopy and the absence of specific clinical signs, diagnosis is difficult and often delayed for several months after the onset of symptoms. The role of adjuvant treatment after R0 surgical resection is not yet clear, given the paucity of series reported in the literature. The combination of capecitabine and oxalliplatin is highly active, with a median overall survival of 15 months in advanced and metastatic patients. Through this article, we have been able to describe the clinical and para-clinical aspects and the different therapeutic modalities.